2. Search Result
Search Result
Results for "

atherosclerosis and vascular diseases

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

1

Biochemical Assay Reagents

8

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W040055
    Neopterin

    D-(+)-Neopterin; D-erythro-Neopterin

    		 NF-κB PPAR ERK Raf Src Cardiovascular Disease Inflammation/Immunology
    Neopterin is an immune system activator metabolized by GTP and can be produced by activated macrophages. Neopterin has the potential to resist vascular inflammation and atherosclerosis. Neopterin inhibits the phosphorylation of NF-κB and promotes the expression of PPAR-γ, thereby suppressing the inflammatory response of vascular endothelial cells, reducing the formation of macrophage foam cells, and regulating the migration and proliferation of vascular smooth muscle cells. Neopterin can be used in research fields such as cardiovascular diseases (such as atherosclerosis), inflammation-related diseases and tumor immunomonitoring .
    Neopterin
  • HY-125864
    Fibrinogen (Bovine)

    		Interleukin Related NF-κB Inflammation/Immunology
    Fibrinogen (Bovine) is a selective proteolytic molecule that can be activated by thrombin to assemble fibrin clots. Fibrinogen can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 and MCP-1. Fibrinogen plays a key role in blood clotting, thrombosis, atherosclerosis and the pathological development of venous grafts, and can be used in the study of blood clotting and vascular diseases .
    Fibrinogen (Bovine)
  • HY-112417
    Ki11502

    		PDGFR FLT3 Apoptosis Akt PERK Bcl-2 Family Cardiovascular Disease Cancer
    Ki11502 is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the activity of PDGF β/α receptors with IC50 values less than 10 nM. Ki11502 selectively inhibits PDGF β receptor phosphorylation, proliferation, and proteoglycan synthesis in human vascular smooth muscle cells. Ki11502 can induce Apoptosis) and exhibits profound antiproliferative effects on select subsets of leukemia, including those with Imatinib (HY-15463) resistant mutations. Ki11502 is highly suitable for studying the role of PDGF in vascular diseases, particularly the role of proteoglycans in atherosclerosis .
    Ki11502
  • HY-113224
    Desmosterol
    5 Publications Verification

    		 Endogenous Metabolite LXR Fatty Acid Synthase (FASN) Interleukin Related Reactive Oxygen Species NOD-like Receptor (NLR) Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Desmosterol is a cholesterol-like molecule. In the Bloch pathway of cholesterol biosynthesis, Desmosterol is a direct precursor of cholesterol. As an endogenous metabolite, Desmosterol is used to study cholesterol metabolism . Desmosterol is an LXR activator and SREBP inhibitor, which can suppress macrophage inflammasome activation and prevent vascular inflammation and atherosclerosis. A reduction in Desmosterol promotes the production of mitochondrial reactive oxygen species (ROS) in macrophages and pyrin domain-dependent inflammasome activation of NLRP3. Desmosterol holds potential for research in inflammation, metabolism, and cardiovascular diseases .
    Desmosterol
  • HY-N2464
    Maltotetraose
    1 Publications Verification

    Amylotetraose; Fujioligo 450; α-1,4-Tetraglucose

    		 TNF Receptor Endogenous Metabolite Bacterial Integrin NF-κB Cardiovascular Disease Inflammation/Immunology
    Maltotetraose can serve as a substrate for enzyme-linked assays to measure amylase activity in biological fluids. Maltotetraose has oral active, and reduces TNF-α-induced inflammatory responses by inhibiting NF-κB activity and decreasing ICAM-1 expression. Maltotetraose also inhibits PDGF-induced vascular smooth muscle cell migration and neovascularization. Additionally, Maltotetraose derivatives can function as probes for detecting bacterial infections by targeting the maltodextrin transporter. With good long-term safety, Maltotetraose holds promise for research in atherosclerosis-related diseases .
    Maltotetraose
  • HY-19399A
    (±)-Iroxanadine

    BRX 005; BRX 235

    		 p38 MAPK HSP Cardiovascular Disease
    (±)-Iroxanadine (BRX 005; BRX 235), a vasculoprotector, is a p38 kinase and HSP protein activator. (±)-Iroxanadine has the potential for atherosclerosis and vascular diseases research .
    (±)-Iroxanadine
  • HY-19399D
    Iroxanadine hydrochloride

    (-)-BRX 005 hydrochloride; (-)-BRX 235 hydrochloride

    		 p38 MAPK HSP Cardiovascular Disease
    Iroxanadine (BRX 005) hydrochloride is a vasculoprotector. Iroxanadine is a p38 kinase and HSP protein dual activator. Iroxanadine hydrochloride has the potential for atherosclerosis and vascular diseases research .
    Iroxanadine hydrochloride
  • HY-19399
    Iroxanadine

    (-)-BRX 005; (-)-BRX 235

    		 p38 MAPK HSP Cardiovascular Disease
    Iroxanadine (BRX 005) is a vasculoprotector. Iroxanadine is a p38 kinase and HSP protein dual activator. Iroxanadine has the potential for atherosclerosis and vascular diseases research .
    Iroxanadine
  • HY-19399B
    Iroxanadine sulfate

    (-)-BRX 005 sulfate; (-)-BRX 235 sulfate

    		 p38 MAPK HSP Cardiovascular Disease
    Iroxanadine (BRX 005) sulfate is a vasculoprotector. Iroxanadine is a p38 kinase and HSP protein dual activator. Iroxanadine sulfate has the potential for atherosclerosis and vascular diseases research .
    Iroxanadine sulfate
  • HY-19399C
    Iroxanadine hydrobromide

    (-)-BRX 005 hydrobromide; (-)-BRX 235 hydrobromide

    		 p38 MAPK HSP Cardiovascular Disease
    Iroxanadine hydrobromide (BRX 005) is a vasculoprotector. Iroxanadine is a p38 kinase and HSP protein dual activator. Iroxanadine hydrobromide has the potential for atherosclerosis and vascular diseases research .
    Iroxanadine hydrobromide
  • HY-113224R
    Desmosterol (Standard)

    		Endogenous Metabolite LXR Fatty Acid Synthase (FASN) Interleukin Related Reactive Oxygen Species NOD-like Receptor (NLR) Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Desmosterol (Standard) is the analytical standard of Desmosterol. This product is intended for research and analytical applications. Desmosterol is a cholesterol-like molecule. In the Bloch pathway of cholesterol biosynthesis, Desmosterol is a direct precursor of cholesterol. As an endogenous metabolite, Desmosterol is used to study cholesterol metabolism [1]. Desmosterol is an LXR activator and SREBP inhibitor, which can suppress macrophage inflammasome activation and prevent vascular inflammation and atherosclerosis. A reduction in Desmosterol promotes the production of mitochondrial reactive oxygen species (ROS) in macrophages and pyrin domain-dependent inflammasome activation of NLRP3. Desmosterol holds potential for research in inflammation, metabolism, and cardiovascular diseases [1][2][3].
    Desmosterol (Standard)
  • HY-125740
    Malvidin-3-glucoside chloride

    Malvidin-3-O-glucoside chloride; Oenin chloride

    		 NF-κB TNF Receptor NO Synthase Interleukin Related Inflammation/Immunology
    Malvidin-3-glucoside (Malvidin-3-O-glucoside; Oenin) chloride is an orally active inhibitor of the NF-κB pathway, which blocks inflammatory responses induced by TNF-α, reduces IκB-α degradation and p65 nuclear translocation, and upregulates endothelial nitric oxide synthase eNOS to increase NO production. Malvidin-3-glucoside chloride exerts anti-inflammatory and antioxidant effects by inhibiting pro-inflammatory molecules such as MCP-1, ICAM-1, and IL-6, and regulating intestinal microorganisms and metabolites, while protecting endothelial cells and improving intestinal microecological dysbiosis under inflammatory conditions. Malvidin-3-glucoside chloride can be used to study chronic inflammatory-related diseases such as atherosclerosis and inflammatory bowel disease, and has the potential to prevent vascular inflammation and improve intestinal health .
    Malvidin-3-glucoside chloride
  • HY-125740R
    Malvidin-3-glucoside chloride (Standard)

    Malvidin-3-O-glucoside chloride (Standard); Oenin chloride (Standard)

    		 Reference Standards Interleukin Related NO Synthase NF-κB TNF Receptor Metabolic Disease Inflammation/Immunology
    Malvidin-3-glucoside (Malvidin-3-O-glucoside; Oenin) chloride (Standard) is the analytical standard of Malvidin-3-glucoside chloride (HY-125740). This product is intended for research and analytical applications. Malvidin-3-glucoside chloride is an orally active inhibitor of the NF-κB pathway, which blocks inflammatory responses induced by TNF-α, reduces IκB-α degradation and p65 nuclear translocation, and upregulates endothelial nitric oxide synthase eNOS to increase NO production. Malvidin-3-glucoside chloride exerts anti-inflammatory and antioxidant effects by inhibiting pro-inflammatory molecules such as MCP-1, ICAM-1, and IL-6, and regulating intestinal microorganisms and metabolites, while protecting endothelial cells and improving intestinal microecological dysbiosis under inflammatory conditions. Malvidin-3-glucoside chloride can be used to study chronic inflammatory-related diseases such as atherosclerosis and inflammatory bowel disease, and has the potential to prevent vascular inflammation and improve intestinal health .
    Malvidin-3-glucoside chloride (Standard)
  • HY-N1353
    Rhamnocitrin
    1 Publications Verification

    		 p38 MAPK Cardiovascular Disease Inflammation/Immunology
    Rhamnocitrin is an anti-inflammatory and antioxidant agent that targets STIM-1, NFATc3 and MAPK pathways and can scavenge DPPH (IC50=28.38 mM). Rhamnocitrin selectively inhibits oxidative stress and inflammatory responses in vascular endothelial cells and neurons. Rhamnocitrin up-regulates miR-185 to inhibit STIM-1-mediated store-operated calcium entry (SOCE), thereby blocking NFATc3 nuclear translocation and downstream inflammatory factor expression, while inducing heme oxygenase HO-1 expression and regulating the ERK/p38 MAPK pathway, inhibiting antioxidant and pro-inflammatory cytokines (such as IL-6, IL-8) and adhesion molecules (such as ICAM-1, VCAM-1). Rhamnocitrin can be used in the study of endothelial-related inflammatory diseases (such as sepsis, acute lung injury, atherosclerosis) and neuroprotection (such as oxidative damage of PC12 cells) .
    Rhamnocitrin
  • HY-N1353R
    Rhamnocitrin (Standard)

    		Others p38 MAPK Cardiovascular Disease Inflammation/Immunology
    Rhamnocitrin (Standard) is the analytical standard of Rhamnocitrin. This product is intended for research and analytical applications. Rhamnocitrin is an anti-inflammatory and antioxidant agent that targets STIM-1, NFATc3 and MAPK pathways and can scavenge DPPH (IC50=28.38 mM). Rhamnocitrin selectively inhibits oxidative stress and inflammatory responses in vascular endothelial cells and neurons. Rhamnocitrin up-regulates miR-185 to inhibit STIM-1-mediated store-operated calcium entry (SOCE), thereby blocking NFATc3 nuclear translocation and downstream inflammatory factor expression, while inducing heme oxygenase HO-1 expression and regulating the ERK/p38 MAPK pathway, inhibiting antioxidant and pro-inflammatory cytokines (such as IL-6, IL-8) and adhesion molecules (such as ICAM-1, VCAM-1). Rhamnocitrin can be used in the study of endothelial-related inflammatory diseases (such as sepsis, acute lung injury, atherosclerosis) and neuroprotection (such as oxidative damage of PC12 cells) .
    Rhamnocitrin (Standard)